



Express Mail No.: EV 475 141 100 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Charlotte A. Kensil

Confirmation No: 2171

Application No.: 09/760,506

Group Art Unit: 1636

Filed: January 12, 2001

Examiner: Celine X. Qian

For: INNATE IMMUNITY STIMULATING
COMPOSITIONS OF CPG AND
SAPONIN AND METHODS THEREOF

Attorney Docket No.: 8449-153

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby direct the Examiner's attention to the references C01-C11 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicants." Copies of References C01-C11 are being submitted herewith.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Submission of this Supplemental Information Disclosure Statement is after the mailing date of the first Office Action on the merits; therefore, pursuant to 37 C.F.R.

§ 1.97(c), an estimated fee of **\$180.00** is due for the filing of this Information Disclosure Statement. Please charge the required fee, including any deficiencies in the amount estimated to be due, to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: October 20, 2004

Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

OCT 20 2004

LIST OF REFERENCES CITED BY APPLICANT

(Use additional sheets if necessary)

ATTY DOCKET NO.

8449-153

APPLICATION NO.

09/760,506

APPLICANT

Charlotte Kensil

FILING DATE

January 12, 2001

GROUP

1636

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01						
	A02						
	A03						
	A04						
	A05						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Abbas <i>et al.</i> , in <u>Cellular and Molecular Immunology</u> , 3 rd ed., WB Saunders Company, Philadelphia, PA, 1997, p. 269
C02	Gajewski <i>et al.</i> , "The P815 Mastocytoma Tumor Model" in Current Protocols in Immunology (2001) 20.4.1-20.4.18
C03	Kensil <i>et al.</i> , 1998, "QS-21 and QS-7: purified saponin adjuvants," Dev Biol Stand 92: 41-47
C04	Kimura <i>et al.</i> , 1999, "Immunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency," Eur J Immunol 29:1532-42
C05	Mescher <i>et al.</i> 1996, "Immunotherapy of Established Murine Tumors with Large Multivalent Immunogen and Cyclophosphamide," J Immunother Emphasis Tumor Immunol 19:102-112
C06	Nakagawa <i>et al.</i> , 1998, "The Angiogenic Effect of Tissue Factor on Tumors and Wounds," Semin Thromb Hemost. 24:207-210
C07	Rakmilevich <i>et al.</i> , 1996, "Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors," Proc. Natl. Acad. Sci. USA 93:6291-6296
C08	Seya <i>et al.</i> , 2000, "Innate Immune Therapy for Cancer: Screen for Molecules Capable of Activating the Innate Immune System" in Cancer Gene Therapy: Past Achievements and Future Challenges, ed. Habib <i>et al.</i> , Kluwer Academic/Plenum Publishers, New York
C09	Snapper <i>et al.</i> , 1987, "Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production," Science 236: 944-947
C10	Whiteside <i>et al.</i> , 1994, "Role of Human Natural Killer Cells in Health and Disease," Clin Diagn Lab Immunology 1:125-133
C11	Yamamura <i>et al.</i> , 1976, "Immunotherapy of Cancer with Cell Wall Skeleton of Mycobacterium Bovis-Bacillus Calmette-Guerin: Experimental and Clinical Results," Ann NY Acad Sci 277:209-227

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.